DSS, Inc. Subsidiary Announces Strategic Merger

NEW YORK, June 24, 2025 — DSS, Inc. (NYSE American: DSS), a multinational company with operations spanning blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets, has announced a significant development involving its subsidiary, Impact BioMedical Inc. (Impact). The company revealed that Impact has entered into a definitive merger agreement with Dr. Ashleys Limited (Dr. Ashleys), a global pharmaceutical company.

Under the terms of the merger agreement, Dr. Ashleys will acquire Impact through a reverse merger, resulting in the formation of a new combined entity. This newly formed company will be publicly traded on the NYSE American under the name “Dr Ashleys Limited.” This strategic move is expected to enhance the capabilities and market reach of both companies, particularly in the biohealth innovation sector.

DSS, Inc., which serves clients across the United States, is listed on the NYSE American with a market capitalization of $8,910,000 USD. As of June 22, 2025, the company’s close price was $0.95, with a 52-week high of $1.754 on June 26, 2024, and a 52-week low of $0.72 on May 6, 2025.

This merger is a significant step for DSS, Inc. as it continues to expand its influence and operations across various industries. The integration of Impact BioMedical Inc. into Dr. Ashleys Limited is anticipated to bring synergies that will drive growth and innovation in the pharmaceutical and biohealth sectors.

For more information about DSS, Inc. and its diverse business segments, visit www.dsssecure.com .